For ACS patients the early use of high-dose/potency statins significantly reduces the risk of death or a major cardiovascular event in comparison with standard lipid lowering regimens. Overall, modelling of the cost-effectiveness of high-dose relative to standard-dose statins appears to support the use of high-dose statins for ACS patients. If we accept that the model’s results, derived from the US health-care system, are generalisable to the UK, intensive lipid lowering with high-dose statins seems highly likely to be cost-effective at drug price differentials and willingness to pay thresholds likely to be operating in the NHS.